FAS opened a case against “Novartis Pharma” Ltd.

20-04-2017 | 14:18

The company is suspected of fixing monopolistically high price for “Tyverb” medicinal drug

The Federal Antimonopoly Service (FAS Russia) opened a case against “Novartis Pharma” Ltd. for breaching Clause 1 Part 1 Article 10 of the Federal Law “On Protection of Competition”1.

FAS sees signs of breaking the antimonopoly law in an unfeasible increase of price for a monopoly drug “Tyverb” (the “Lapatinib” International Non-Proprietary Name) by 35 % in January 2016.

The case was initiated upon a statement from the Moscow Government that buys “Tyverb”for patients under the programme of government guarantees of free medical aid to the population.

Head of FAS Department for Control over Social Sphere and Trade, Timophey Nizhegorodtsev, commented the case: “In the course of the investigation Novartis Pharma” shall have to explain the reasons and justify the growth of prices for “Tyverb” medicinal drug from 118,000 to 159,000 Rub per package in view of the company’s monopolistic position on the market.

Clause 1 Part 1 Article 10 of the Federal Law “On Protection of Competition” prohibits actions (omissions) of an economic entity with the dominant position that lead or can lead to preventing, restricting, eliminating competition and (or) infringing the interest of other persons (economic entities) in business activity or consumers at large, particularly, fixing, maintaining monopolistically high price of goods.

Site Map

News & Events Press Releases Media Releases Image Library About the FAS Russia What We Do General Information Mission, Goals, Values Priority Setting Institutional Memory Stakeholders Engagement Center for Education and Methodics Our History Our Structure Powers of Head and Deputy Heads Our Ratings GCR Using our website International Cooperation Treaties & Agreements International Working Groups Working Group on Research of Competition Issues in the Market of International Telecommunications (Roaming) Meetings Working Group for Studying Competition Problems in the Pharmaceutical Sector Concept Note Meetings OECD Competition Committee OECD meetings 2013 OECD meetings 2014 OECD meetings 2015 OECD meetings 2016 OECD meetings 2017 FAS Annual Reports OECD-GVH RCC RCC Newsletter ICAP Council on Advertising Headquarters for Joint Investigations UNCTAD 13th session IGE UNCTAD Resolution Russian contributions 14th session IGE UNCTAD Resolution Russian contributions 15th session IGE UNCTAD 16th session IGE UNCTAD UN Conference Resolution of the Conference Russian contributions EEU Model Law on Competition ICN BRICS WG (Markets of Social Importance) EU APEC Competition Policy and Law Group Annual meetings Projects ERRA Full Members Organizational Structure Archive Working Group on Investigating Issues on Pricing in the Oil and Oil Product Markets and Methods of their Functioning Meetings Document Library Legislation Reports & Analytics Cases & decisions Contacts Give feedback Contact us Links Authorities Worldwide